Related Experiment Video
Updated: Feb 19, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Early-onset epileptic encephalopathy with de novo SCN8A mutation
Yangyang Xiao1, Jie Xiong1, Ding'an Mao1
1Department of Pediatrics, Second Xiangya Hospital, Central South University, 139 Mid Renmin Road, Furong District, Changsha City, Hunan Province 410011, China.
Insights
A de novo SCN8A gene mutation was identified in an infant with early-onset epileptic encephalopathy (EOEE). This finding highlights SCN8A
Area of Science:
- Genetics
- Neuroscience
- Molecular Biology
Background:
- Early-onset epileptic encephalopathies (EOEEs) are severe neurodevelopmental disorders with unknown causes.
- Intractable seizures and developmental impairment characterize these conditions, often beginning in infancy.
- Sudden unexpected death in epilepsy (SUDEP) is a significant concern in these patients.
Observation:
- A parent-offspring trio underwent genetic testing using a 511-gene epilepsy panel.
- The study focused on a male infant diagnosed with EOEE, presenting with refractory seizures, intellectual disability, and motor abnormalities.
- The child tragically died from SUDEP at 26 months of age.
Findings:
- A de novo heterozygous missense mutation (c.4423G > A; Gly1475Arg) was identified in the SCN8A gene.
- This mutation is located in the inactivation gate of the SCN8A gene, which encodes the voltage-gated sodium channel subunit alpha 8.
- The findings strengthen the link between SCN8A gene mutations and EOEE.
Implications:
- Increased attention is needed for the risk of SUDEP in patients with SCN8A-related EOEE.
- Further research into the pathogenic mechanisms of SCN8A mutations in the inactivation gate is warranted.
- Understanding these mechanisms in both neuronal and cardiac tissues may reveal therapeutic targets.
Abstract:
Early-onset epileptic encephalopathies (EOEEs) are clinically and genetically heterogeneous disorders characterized by intractable seizures and unremitting interictal paroxysmal epileptiform activity. Consequently, these syndromes impair neurodevelopment during the first year of life. Currently, the etiology of these disorders is largely unknown. In this study, Childhood-Onset Epilepsy Gene Panel Testing (containing 511 epilepsy-related genes) was performed in a parent-offspring trio. In this family, the son had refractory seizures, intellectual disability, and motor abnormalities, and he was diagnosed with EOEE. The boy later died from a sudden unexpected death in epilepsy (SUDEP) at the age of 26 months. In this case, we identified a de novo mutation (c.4423G > A; glycine [Gly]1475 arginine [Arg]) classified as heterozygous missense located in the inactivation gate section of the SCN8A (voltage-gated sodium-channel type VIII alpha subunit) gene. This result strengthens the association between the SCN8A gene and EOEE, and more attention should be given to its high rate of SUDEP. Further studies to determine the pathogenic mechanisms of SCN8A mutations should be warranted at the inactivation gate section of this sodium channel in both neurons and cardiac muscles.
More Related Videos
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
06:58A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy
Published on: July 12, 2021
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...